Citations

Citations to this article as recorded by  

• Crohn’s Disease Among the Poorest Billion: Burden of Crohn’s Disease in Low- and Lower-Middle-Income Countries
  Ruma Rajbhandari, Samantha Blakemore, Neil Gupta, Sara Mannan, Klejda Nikolli, Alison Yih, Laura Drown, Gene Bukhman
  Digestive Diseases and Sciences.2023; 68(4): 1226.     CrossRef
• The cost of illness analysis of inflammatory bowel disease
  Majid Pakdin, Leila Zarei, Kamran Bagheri Lankarani, Sulmaz Ghahramani
  BMC Gastroenterology.2023;[Epub]     CrossRef
• Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South‐East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease‐Emerging Nations' Consortium
  Rupa Banerjee, Partha Pal, Ida Hilmi, Uday C Ghoshal, Devendra C Desai, Mohammed Masudur Rahman, Usha Dutta, Syed A Mohiuddin, Munnera Al Mohannadi, Mathew Philip, Ganesh N Ramesh, Madunil A Niriella, Arjuna P De Silva, Hithanadura Janaka de Silva, Pises
  Journal of Gastroenterology and Hepatology.2022; 37(6): 1004.     CrossRef
• Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia
  Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng
  The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076.     CrossRef
• Crohn’s disease in low and lower-middle income countries: A scoping review
  Ruma Rajbhandari, Samantha Blakemore, Neil Gupta, Alma J Adler, Christopher Allen Noble, Sara Mannan, Klejda Nikolli, Alison Yih, Sameer Joshi, Gene Bukhman
  World Journal of Gastroenterology.2020; 26(43): 6891.     CrossRef
• Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
  Satoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, Young Ho Kim, Dong Soo Han, Hirotoshi Yuasa, Junichi Tabira, Naoki Isogawa, Shoko Arai, Isao Kawaguchi, Toshifumi Hibi
  Intestinal Research.2018; 16(2): 233.     CrossRef
• Delineating inflammatory bowel disease through transcriptomic studies: current review of progress and evidence
  Seow-Neng Chan, Eden Ngah Den Low, Raja Affendi Raja Ali, Norfilza Mohd Mokhtar
  Intestinal Research.2018; 16(3): 374.     CrossRef
• The role of the microbiome and the use of probiotics in gastrointestinal disorders in adults in the Asia‐Pacific region ‐ background and recommendations of a regional consensus meeting
  Uday C Ghoshal, Kok‐Ann Gwee, Gerald Holtmann, Yanmei Li, Soo Jung Park, Marcellus Simadibrata, Kentaro Sugano, Kaichun Wu, Eamonn M M Quigley, Henry Cohen
  Journal of Gastroenterology and Hepatology.2018; 33(1): 57.     CrossRef
• Ophthalmologic manifestations in patients with inflammatory bowel disease
  Hye Jin Lee, Hyun Joo Song, Jin Ho Jeong, Heung Up Kim, Sun-Jin Boo, Soo-Young Na
  Intestinal Research.2017; 15(3): 380.     CrossRef
• Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn’s disease
  Kyunghwan Oh, Eun Hye Oh, Seunghee Baek, Eun Mi Song, Gwang-Un Kim, Myeongsook Seo, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, John Green
  PLOS ONE.2017; 12(6): e0179266.     CrossRef
• Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases
  Young Sun Kim, Sung-Ae Jung, Kang-Moon Lee, Soo Jung Park, Tae Oh Kim, Chang Hwan Choi, Hyun Gun Kim, Won Moon, Chang Mo Moon, Hye Kyoung Song, Soo-Young Na, Suk-Kyun Yang
  Intestinal Research.2017; 15(3): 338.     CrossRef
• Microbiome and colorectal cancer: Unraveling host-microbiota interactions in colitis-associated colorectal cancer development
  Mingsong Kang, Alberto Martin
  Seminars in Immunology.2017; 32: 3.     CrossRef
• Overall and cause‐specific mortality in Korean patients with inflammatory bowel disease: A hospital‐based cohort study
  Ho‐Su Lee, Jaewon Choe, Seon‐Ok Kim, Sun‐Ho Lee, Hyo Jeong Lee, Hyungil Seo, Gwang‐Un Kim, Myeongsook Seo, Eun Mi Song, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Kyung‐Jo Kim, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Yong Sik Yoon, Chang S
  Journal of Gastroenterology and Hepatology.2017; 32(4): 782.     CrossRef
• Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
  Toshifumi Hibi, Yuya Imai, Yoko Murata, Nobuko Matsushima, Richuan Zheng, Christopher Gasink
  Intestinal Research.2017; 15(4): 475.     CrossRef
• Protective effects of heat-killed Lactococcus lactis subsp. lactis BF3, isolated from the intestine of chum salmon, in a murine model of DSS-induced inflammatory bowel disease
  Toru NAKATA, Shino HIRANO, Yasushi YOKOTA, Hajime TAKAHASHI, Bon KIMURA, Takashi KUDA, Tadashi ETO, Michiko KATO
  Bioscience of Microbiota, Food and Health.2016; 35(3): 137.     CrossRef
• Current status of biosimilars in the treatment of inflammatory bowel diseases
  Dong Il Park
  Intestinal Research.2016; 14(1): 15.     CrossRef
• Influence of a Positive Family History on the Clinical Course of Inflammatory Bowel Disease
  Sung Wook Hwang, Min Seob Kwak, Wan Soo Kim, Jeong-Mi Lee, Sang Hyoung Park, Ho-Su Lee, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
  Journal of Crohn's and Colitis.2016; 10(9): 1024.     CrossRef
• Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn’s Disease: Results from the CONNECT Study
  Jee Hye Kwon, Jong Pil Im, Byong Duk Ye, Jae Hee Cheon, Hyun Joo Jang, Kang Moon Lee, You Sun Kim, Sang Wook Kim, Young Ho Kim, Geun Am Song, Dong Soo Han, Won Ho Kim, Joo Sung Kim
  Gut and Liver.2016; 10(4): 595.     CrossRef
• The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West?
  Rashid N.S. Lui, Siew C. Ng
  Inflammatory Intestinal Diseases.2016; 1(2): 78.     CrossRef

Citations

Citations to this article as recorded by  

• How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
  You Sun Kim
  The Korean Journal of Gastroenterology.2018; 71(2): 74.     CrossRef
• Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis
  Yoon Jee Lee, Jae Hee Cheon, Jae Hyun Kim, SunHo Yoo, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim
  Yonsei Medical Journal.2017; 58(1): 144.     CrossRef

Citations

Citations to this article as recorded by  

• Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn’s disease: a Korean nationwide population-based study
  Yu Kyung Jun, Eunjeong Ji, Hye Ran Yang, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
  Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
• Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy
  Ahmed B. Bayoumy, A. R. Ansari, C. J. J. Mulder, K. Schmiegelow, Timothy Florin, N. K. H. De Boer
  Clinical Pharmacokinetics.2024; 63(8): 1089.     CrossRef
• Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling
  Jiryeon Jang, Sehoon Jeong
  BioChip Journal.2023; 17(4): 403.     CrossRef
• Association of genetic polymorphism of NUDT15, TPMT and ITPA gene in the toxicity and efficacy of azathioprine-based regimen in Egyptian inflammatory bowel disease patients
  Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem
  Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub]     CrossRef
• A review article of inflammatory bowel disease treatment and pharmacogenomics
  Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem
  Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub]     CrossRef
• Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review
  Devendra Desai, Anuraag Jena, Vishal Sharma, Toshifumi Hibi
  Expert Review of Clinical Pharmacology.2023; 16(7): 643.     CrossRef
• Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
  Yoon-Zi Kim, Ben Kang, Eun-Sil Kim, Yiyoung Kwon, Yon-Ho Choe, Mi-Jin Kim
  Biomedicines.2023; 11(9): 2575.     CrossRef
• Effect of NUDT15 polymorphisms on early hematological safety of low‐dose azathioprine in Chinese patients with pemphigus vulgaris: A prospective cohort study
  Xingli Zhou, Liangliang Cheng, Yiyi Wang, Hui Gou, Ke Ju, TianJiao Lan, Tongying Zhan, GaoJie Li, Yuanxia Gu, Yeting Sun, Yan Xu, Yukun Sun, Yanhong Zhou, Wei Li
  The Journal of Dermatology.2022; 49(4): 402.     CrossRef
• Use of thiopurines in inflammatory bowel disease: an update
  Arshdeep Singh, Ramit Mahajan, Saurabh Kedia, Amit Kumar Dutta, Abhinav Anand, Charles N. Bernstein, Devendra Desai, C. Ganesh Pai, Govind Makharia, Harsh Vardhan Tevethia, Joyce WY Mak, Kirandeep Kaur, Kiran Peddi, Mukesh Kumar Ranjan, Perttu Arkkila, Ra
  Intestinal Research.2022; 20(1): 11.     CrossRef
• Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder
  Wenjuan Huang, Liang Wang, Junhui Xia, Wenyu Li, Min Wang, Jian Yu, Qinying Li, Bei Wang, Juyuan Pan, Lei Du, Jianhua Ma, Hongmei Tan, Xuechun Chang, Chuanzhen Lu, Chongbo Zhao, Jiahong Lu, Lei Zhou, Jingzi ZhangBao, Chao Quan
  European Journal of Neurology.2022; 29(8): 2343.     CrossRef
• Minimal risk of lymphoma and non‐melanoma skin cancer despite long‐term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India
  Mukesh Kumar Ranjan, Bhaskar Kante, Sudheer Kumar Vuyyuru, Peeyush Kumar, Sandeep K Mundhra, Rithvik Golla, Raju Sharma, Peush Sahni, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
  Journal of Gastroenterology and Hepatology.2022; 37(8): 1544.     CrossRef
• NUDT15Genotyping in Thiopurine Drug Therapy
  Jong Kwon Lee, Rihwa Choi, Soo-Youn Lee
  Laboratory Medicine Online.2022; 12(4): 217.     CrossRef
• Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis
  Qiang Miao, Lin Yan, Yanhong Zhou, Yi Li, Yuangao Zou, Lanlan Wang, Yangjuan Bai, Junlong Zhang
  Scientific Reports.2021;[Epub]     CrossRef
• Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
  You Sun Kim
  Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
• Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease
  Kang Chao, Yibiao Huang, Xia Zhu, Jian Tang, Xueding Wang, Lang Lin, Huili Guo, Caibin Zhang, Miao Li, Qingfan Yang, Jie Huang, Lingna Ye, Pinjin Hu, Min Huang, Qian Cao, Xiang Gao
  Alimentary Pharmacology & Therapeutics.2021; 54(9): 1124.     CrossRef
• NUDT15: A bench to bedside success story
  Ann M. Moyer
  Clinical Biochemistry.2021; 92: 1.     CrossRef
• Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations
  Kanyarat Khaeso, Sariya Udayachalerm, Patcharee Komvilaisak, Su-on Chainansamit, Kunanya Suwannaying, Napat Laoaroon, Pitchayanan Kuwatjanakul, Nontaya Nakkam, Chonlaphat Sukasem, Apichaya Puangpetch, Wichittra Tassaneeyakul, Nathorn Chaiyakunapruk
  Frontiers in Pharmacology.2021;[Epub]     CrossRef
• Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
  Ji Young Chang, Jae Hee Cheon
  Precision and Future Medicine.2021; 5(4): 151.     CrossRef
• Sexual Dysfunction and Fertility Problems in Men with Inflammatory Bowel Disease
  Yong Eun Park, Tae Oh Kim
  The World Journal of Men's Health.2020; 38(3): 285.     CrossRef
• Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases
  Ji Young Chang, Soo Jung Park, Eun Suk Jung, Sung-Ae Jung, Chang Mo Moon, Jaeyoung Chun, Jae Jun Park, Eun Sun Kim, Yehyun Park, Tae-Il Kim, Won Ho Kim, Jae Hee Cheon
  Clinical Gastroenterology and Hepatology.2020; 18(9): 2010.     CrossRef
• Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
  Hiroshi Nakase
  Gut and Liver.2020; 14(1): 7.     CrossRef
• Adjustment of azathioprine dose should be based on a lower 6‐TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers
  Ben Kang, Tae Jun Kim, Jaeyoung Choi, Sun‐Young Baek, Soohyun Ahn, Rihwa Choi, Soo‐Youn Lee, Yon Ho Choe
  Alimentary Pharmacology & Therapeutics.2020; 52(3): 459.     CrossRef
• NUDT15 genotyping during azathioprine treatment in patients with inflammatory bowel disease: implications for a dose-optimization strategy
  Ye Xu, Yu-Qi Qiao, Han-Yang Li, Mi Zhou, Chen-Wen Cai, Jun Shen, Zhi-Hua Ran
  Gastroenterology Report.2020; 8(6): 437.     CrossRef
• Complete remission of refractory pemphigus vulgaris in a Chinese patient with mutated NUDT15 by combination of minimal doses of azathioprine and prednisone
  Xing‐Li Zhou, Tong‐Ying Zhan, Yan‐Hong Zhou, Krista Shrestha, Tian‐Jiao Lan, Wei Li
  Dermatologic Therapy.2020;[Epub]     CrossRef
• Prevention of thiopurine-induced early leukopenia in a Korean pediatric patient with Crohn’s disease who turned out to possess homozygous mutations in NUDT15 R139C
  Jaewoan Bae, Byung-Ho Choe, Ben Kang
  Yeungnam University Journal of Medicine.2020; 37(4): 332.     CrossRef
• NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine‐induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India
  Rupa Banerjee, Vishnubhotla Venkata Ravikanth, Partha Pal, Govardhan Bale, Urmila Steffie Avanthi, Idan Goren, B. Ganesh Girish, Sasikala Mitnala, D. Nageshwar Reddy
  Alimentary Pharmacology & Therapeutics.2020; 52(11-12): 1683.     CrossRef
• Improving the quality of care for inflammatory bowel disease
  Byong Duk Ye, Simon Travis
  Intestinal Research.2019; 17(1): 45.     CrossRef
• NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients With Autoimmune Hepatitis and Related Cirrhosis
  Xiaoli Fan, Dandan Yin, Ruoting Men, Heng Xu, Li Yang
  Frontiers in Pharmacology.2019;[Epub]     CrossRef
• Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics
  Ji Young Chang, Jae Hee Cheon
  Digestive Diseases and Sciences.2019; 64(9): 2395.     CrossRef
• Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn’s disease patients
  Xia Zhu, Kang Chao, Miao Li, Wen Xie, Hong Zheng, Jin-Xin Zhang, Pin-Jin Hu, Min Huang, Xiang Gao, Xue-Ding Wang
  World Journal of Gastroenterology.2019; 25(38): 5850.     CrossRef
• How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
  You Sun Kim
  The Korean Journal of Gastroenterology.2018; 71(2): 74.     CrossRef
• Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis
  Sarah Cargnin, Armando A. Genazzani, Pier Luigi Canonico, Salvatore Terrazzino
  Pharmacological Research.2018; 135: 102.     CrossRef
• Treatment of Autoimmune Bullous Disorders in Pregnancy
  Carolyn J. Kushner, Josef Symon S. Concha, Victoria P. Werth
  American Journal of Clinical Dermatology.2018; 19(3): 391.     CrossRef
• Characteristics and management of patients with inflammatory bowel disease between a secondary and tertiary hospitals: a propensity score analysis
  Ki Hwan Song, Eun Soo Kim, Yoo Jin Lee, Byung Ik Jang, Kyeong Ok Kim, Sang Gyu Kwak, Hyun Seok Lee
  Intestinal Research.2018; 16(2): 216.     CrossRef
• Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
  Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
  Intestinal Research.2018; 16(1): 4.     CrossRef
• Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease
  Hong-Hui Wang, Ying He, Hong-Xian Wang, Cheng-Ling Liao, Yu Peng, Li-Jian Tao, Wei Zhang, Hui-Xiang Yang
  World Journal of Gastroenterology.2018; 24(8): 941.     CrossRef
• NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients
  Xiang Fei, Qing Shu, Huaijun Zhu, Bingzhu Hua, Shiying Wang, Ling Guo, Yun Fang, Weihong Ge
  Frontiers in Pharmacology.2018;[Epub]     CrossRef
• Pharmacotherapy of ulcerative colitis – current status and emerging trends
  Hilal Ahmad, Vijay L. Kumar
  Journal of Basic and Clinical Physiology and Pharmacology.2018; 29(6): 581.     CrossRef
• Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment
  Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
  Journal of Gastroenterology and Hepatology.2018; 33(1): 20.     CrossRef
• Postoperative course of Crohn disease according to timing of bowel resection
  Ji Min Lee, Kang-Moon Lee, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, Dong Soo Han, Chang Kyun Lee, Hyun-Ju Park
  Medicine.2018; 97(16): e0459.     CrossRef
• Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
  Sheng Zhang Lim, Eng Wee Chua
  Frontiers in Pharmacology.2018;[Epub]     CrossRef
• Changing treatment paradigms for the management of inflammatory bowel disease
  Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
  The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
• NUDT15,FTO, andRUNX1genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
  Toshiyuki Sato, Tetsuya Takagawa, Yoichi Kakuta, Akihiro Nishio, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Yuko Kita, Takako Miyazaki, Masaki Iimuro, Nobuyuki Hida, Kazutoshi Hori, Hiroki Ikeuchi, Shiro Nakamura
  Intestinal Research.2017; 15(3): 328.     CrossRef
• Second Korean Guideline for the Management of Ulcerative Colitis
  Chang Hwan Choi, Won Moon, You Sun Kim, Eun Soo Kim, Bo-In Lee, Yunho Jung, Yong Sik Yoon, Heeyoung Lee, Dong Il Park, Dong Soo Han
  The Korean Journal of Gastroenterology.2017; 69(1): 1.     CrossRef
• Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
  Jong Pil Im
  Intestinal Research.2017; 15(2): 147.     CrossRef
• Second Korean guidelines for the management of ulcerative colitis
  Chang Hwan Choi, Won Moon, You Sun Kim, Eun Soo Kim, Bo-In Lee, Yunho Jung, Yong Sik Yoon, Heeyoung Lee, Dong Il Park, Dong Soo Han
  Intestinal Research.2017; 15(1): 7.     CrossRef
• Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease
  Kang Chao, Xueding Wang, Qian Cao, Jiaming Qian, Kaichun Wu, Xia Zhu, Hong Yang, Jie Liang, Lang Lin, Zicheng Huang, Yu Zhang, Yibiao Huang, Yinghao Sun, Xianmin Xue, Min Huang, Pinjin Hu, Ping Lan, Xiang Gao
  Inflammatory Bowel Diseases.2017; 23(9): 1592.     CrossRef
• Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?
  Abhinav Vasudevan, Peter R Gibson, Daniel R van Langenberg
  World Journal of Gastroenterology.2017; 23(35): 6385.     CrossRef
• Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
  Chang Soo Eun
  Gut and Liver.2017; 11(1): 3.     CrossRef
• Second Korean Guidelines for the Management of Crohn's Disease
  Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
  The Korean Journal of Gastroenterology.2017; 69(1): 29.     CrossRef
• Second Korean guidelines for the management of Crohn's disease
  Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
  Intestinal Research.2017; 15(1): 38.     CrossRef
• Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn’s Disease: A Hospital-Based Cohort Study
  Sang Hyoung Park, Sung Wook Hwang, Min Seob Kwak, Wan Soo Kim, Jeong-Mi Lee, Ho-Su Lee, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
  Digestive Diseases and Sciences.2016; 61(7): 2060.     CrossRef
• Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn’s disease patients
  Qiuyuan Liu, Yanyan Wang, Qiao Mei, Wei Han, Jing Hu, Naizhong Hu
  Scandinavian Journal of Gastroenterology.2016; 51(9): 1093.     CrossRef
• NUDT15 polymorphisms are better than thiopurine S‐methyltransferase as predictor of risk for thiopurine‐induced leukopenia in Chinese patients with Crohn's disease
  X. Zhu, X.‐D. Wang, K. Chao, M. Zhi, H. Zheng, H.‐L. Ruan, S. Xin, N. Ding, P.‐J. Hu, M. Huang, X. Gao
  Alimentary Pharmacology & Therapeutics.2016; 44(9): 967.     CrossRef
• Influences ofXDHgenotype by gene–gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn’s disease
  Soo-Kyung Park, Myunghee Hong, Byong Duk Ye, Kyung-Jo Kim, Sang Hyoung Park, Dong-Hoon Yang, Sung-Wook Hwang, Min Seob Kwak, Ho-Su Lee, Kyuyoung Song, Suk-Kyun Yang
  Scandinavian Journal of Gastroenterology.2016; 51(6): 684.     CrossRef
• Change in the diagnosis of inflammatory bowel disease: a hospital-based cohort study from Korea
  Ho-Su Lee, Jaewon Choe, Hyo Jeong Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
  Intestinal Research.2016; 14(3): 258.     CrossRef
• Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease
  Ho-Su Lee, Kyung-Wook Jo, Tae Sun Shim, Jin Woo Song, Hyo Jeong Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Jin-Ho Kim, Suk-Kyun Yang
  Journal of Crohn's and Colitis.2015; 9(11): 1053.     CrossRef

With the incidence of inflammatory bowel disease (IBD) increasing rapidly in many Asian countries, including Hong Kong, it is important that patient characteristics are better understood. For example, are the phenotypes, behaviors, complications, and even treatment responses found in Asian patients similar to those of their Western counterparts? To formally address these questions, a properly designed local cohort study is needed. Whilst IBD is still relatively uncommon in Asia, the establishment of a local IBD registry will significantly contribute to the answering of these questions. The Hong Kong IBD registry was established to fill the gap in the understanding of IBD patients, and to foster research into IBD in Hong Kong. The Hong Kong IBD registry is a territory-wide registry that includes all public hospitals in Hong Kong. We included all IBD patients who were currently receiving medical care at these hospitals. With the help of the central computer medical record system of the Hospital Authority of Hong Kong, all clinical events, medications usage, endoscopy records, and laboratory results of patients in the registry were captured. Apart from data collection, the registry is also establishing a bio-specimen bank of blood and stool samples of IBD patients for future research. The IBD registry is a very useful platform for population-based studies on IBD in Asia.

Citations

Citations to this article as recorded by  

• The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study
  Chia-Jung Kuo, Puo-Hsien Le, Wei-Chen Tai, Keng-Liang Wu, Hsu-Heng Yen, Chih-Wei Yen, Shui-Yi Tung, Chen-Shuan Chung, Ming-Yao Su, Cheng-Tang Chiu
  Journal of the Formosan Medical Association.2022; 121(9): 1689.     CrossRef
• Indications, Postoperative Management, and Long-term Prognosis of Crohn’s Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West
  Jeanine H C Arkenbosch, Joyce W Y Mak, Jacky C L Ho, Evelien M J Beelen, Nicole S Erler, Frank Hoentjen, Alexander G L Bodelier, Gerard Dijkstra, Mariëlle Romberg-Camps, Nanne K H de Boer, Laurents P S Stassen, Andrea E van der Meulen, Rachel West, Oddeke
  Inflammatory Bowel Diseases.2022; 28(Supplement): S16.     CrossRef
• Epidemiology and Natural History of Elderly-onset Inflammatory Bowel Disease: Results From a Territory-wide Hong Kong IBD Registry
  Joyce Wing Yan Mak, Carmen Lok Tung Ho, Kylie Wong, Tsz Yan Cheng, Terry Cheuk Fung Yip, Wai Keung Leung, Michael Li, Fu Hang Lo, Ka Man Ng, Shun Fung Sze, Chi Man Leung, Steven Woon Choy Tsang, Edwin Hok Shing Shan, Kam Hon Chan, Belsy C Y Lam, Aric Josu
  Journal of Crohn's and Colitis.2021; 15(3): 401.     CrossRef
• Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
  Choon Jin Ooi, Ida Normiha Hilmi, Hyo-Jong Kim, Umesh Jalihal, Deng-Chyang Wu, Dirk Demuth, Dirk Lindner, Shashi Adsul
  Intestinal Research.2021; 19(1): 71.     CrossRef
• Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
  Rupa Banerjee, Sai Wei Chuah, Ida Normiha Hilmi, Deng-Chyang Wu, Suk-Kyun Yang, Dirk Demuth, Dirk Lindner, Shashi Adsul
  Intestinal Research.2021; 19(1): 83.     CrossRef
• Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study
  Joyce Wing Yan Mak, Jacqueline So, Whitney Tang, Terry Cheuk Fung Yip, Wai Keung Leung, Michael Li, Fu Hang Lo, Ka Man Ng, Shun Fung Sze, Chi Man Leung, Steven Woon Choy Tsang, Edwin Hok Shing Shan, Kam Hon Chan, Belsy C.Y. Lam, Aric J. Hui, Wai Hung Chow
  Scandinavian Journal of Gastroenterology.2020; 55(3): 279.     CrossRef
• Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East
  Masoud M Malekzadeh, Alireza Sima, Sudabeh Alatab, Anahita Sadeghi, Nasser Ebrahimi Daryani, Payman Adibi, Iradj Maleki, Hassan Vossoughinia, Hafez Fakheri, Abbas Yazdanbod, Seyed Alireza Taghavi, Rahim Aghazadeh, Mohammad Hassan Somi, Kazem Zendedel, Hom
  Intestinal Research.2019; 17(3): 330.     CrossRef
• Stopping anti‐tumour necrosis factor therapy in patients with perianal Crohn’s disease
  Joyce Wing Yan Mak, Whitney Tang, Terry Cheuk Fung Yip, Zhi Hua Ran, Shu Chen Wei, Vineet Ahuja, Sudheer Kumar, Wai Keung Leung, Ida Hilmi, Julajak Limsrivilai, Satimai Aniwan, Belsy C. Y. Lam, Kam Hon Chan, Ka Man Ng, Chi Man Leung, Michael K. K. Li, Fu
  Alimentary Pharmacology & Therapeutics.2019; 50(11-12): 1195.     CrossRef
• Direct health‐care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis
  Lung‐Yi Mak, Siew C Ng, Irene O L Wong, Michael K K Li, F H Lo, Marc T L Wong, C M Leung, Steven W C Tsang, K H Chan, S F Sze, Edwin H S Shan, Belsy C Y Lam, Aric J Hui, Ivan F N Hung, Wai K Leung
  Journal of Gastroenterology and Hepatology.2018; 33(1): 141.     CrossRef
• Significant Medical and Surgical Morbidity in Perianal Crohn’s Disease: Results from a Territory-Wide Study
  Wing Yan Mak, Oi Sze Mak, Choon Kin Lee, Whitney Tang, Wai Keung Leung, Marc T L Wong, Alex Shun Fung Sze, Michael Li, Chi Man Leung, Fu Hang Lo, Belsy C Y Lam, Kam Hon Chan, Edwin Hok Shing Shan, Steven Woon Choy Tsang, Aric J Hui, Wai Hung Chow, Francis
  Journal of Crohn's and Colitis.2018;[Epub]     CrossRef

Inflammatory bowel disease (IBD) is defined as a chronic and relapsing inflammatory disorder of the intestine. Intestinal inflammation in IBD has been proposed to be attributable to the interplay between microbial, genetic, environmental, and immunological factors. The incidence and prevalence rates of IBD are rapidly increasing apparently in other parts of the world, with dramatic increases especially in East Asia. Generally, cohort studies are useful for estimating the incidence, prevalence, natural course, prognosis, and risk factors of diseases. In particular, cohort studies performed in Western countries have well described the prevalence, risk factors, and natural course of IBD and investigated its genetic pathophysiology. However, the outcomes of IBD cohort studies performed in Korea are not as persuasive as those of Western studies because of the relatively low prevalence of IBD and short follow-up periods of the cohorts in Korea. Despite this critical limitation, members of the Korean Association for the Study of Intestinal Diseases have demonstrated outstanding results. Some unique features of IBD patients in Korea are well demonstrated, such as thiopurine-induced leukopenia or risks of opportunistic tuberculosis infection in patients receiving tumor necrosis factor-α inhibitors. In this review, the present authors summarized the key points of the results of the cohort studies performed in Korea and explored future perspectives.

Citations

Citations to this article as recorded by  

• CXCL10 as a shared specific marker in rheumatoid arthritis and inflammatory bowel disease and a clue involved in the mechanism of intestinal flora in rheumatoid arthritis
  Yin Guan, Yue Zhang, Yifan Zhu, Yue Wang
  Scientific Reports.2023;[Epub]     CrossRef
• Plasma miRNA Profile of Crohn’s Disease and Rheumatoid Arthritis Patients
  Tatiana D. Saccon, Joseph M. Dhahbi, Augusto Schneider, Yury O. Nunez Lopez, Ahmad Qasem, Marcelo B. Cavalcante, Lauren K. Sing, Saleh A. Naser, Michal M. Masternak
  Biology.2022; 11(4): 508.     CrossRef
• Inflammatory bowel disease in Korea: epidemiology and pathophysiology
  Jung Won Lee, Chang Soo Eun
  The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
• Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study
  Youn I Choi, Yoon Jae Kim, Jun-Won Chung, Kyoung Oh Kim, Hakki Kim, Rae Woong Park, Dong Kyun Park
  JMIR Medical Informatics.2020; 8(4): e15124.     CrossRef
• Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database
  Jiyool Kim, So-Hee Park, Ju-Young Shin
  Korean Journal of Clinical Pharmacy.2020; 30(2): 102.     CrossRef
• Association study between two polymorphisms of tumor necrosis factor ligand superfamily member 15 (TNFSF15) gene and ulcerative colitis in south‐west of Iran
  Marzieh Taheri, Pegah Ghandil, Seyyed Jalal Hashemi, Mehri Ghafourian, Abdol Rahim Masjedi Zadeh, Ata Allah Ghadiri
  Journal of Cellular Biochemistry.2019; 120(5): 8784.     CrossRef
• A new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis in Korea (MOSAIK) cohort study
  Chang Kyun Lee, Kang-Moon Lee, Dong Il Park, Sung-Ae Jung, Yoon Tae Jeen, Young Sook Park, Hyo Jong Kim
  Intestinal Research.2019; 17(1): 1.     CrossRef
• Dermatologic Manifestations in Inflammatory Bowel Disease
  Hyun Yi Suh, Woo Jin Lee, Soo-Young Na
  The Korean Journal of Gastroenterology.2019; 73(5): 285.     CrossRef
• Depressive Symptoms and Quality of Life in the Patients of Inflammatory Bowel Disease
  Jung Won Lee
  Gut and Liver.2017; 11(4): 449.     CrossRef
• Association of inflammatory bowel disease with ankylosing spondylitis and rheumatoid arthritis: A nationwide population-based study
  Jung Min Bae, Ji Yoon Choo, Ki-Jo Kim, Kyung-Su Park
  Modern Rheumatology.2017; 27(3): 435.     CrossRef
• Ophthalmologic manifestations in patients with inflammatory bowel disease
  Hye Jin Lee, Hyun Joo Song, Jin Ho Jeong, Heung Up Kim, Sun-Jin Boo, Soo-Young Na
  Intestinal Research.2017; 15(3): 380.     CrossRef
• Hydrogen-rich water protects against inflammatory bowel disease in mice by inhibiting endoplasmic reticulum stress and promoting heme oxygenase-1 expression
  Nai-Ying Shen, Jian-Bin Bi, Jing-Yao Zhang, Si-Min Zhang, Jing-Xian Gu, Kai Qu, Chang Liu
  World Journal of Gastroenterology.2017; 23(8): 1375.     CrossRef
• Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases
  Young Sun Kim, Sung-Ae Jung, Kang-Moon Lee, Soo Jung Park, Tae Oh Kim, Chang Hwan Choi, Hyun Gun Kim, Won Moon, Chang Mo Moon, Hye Kyoung Song, Soo-Young Na, Suk-Kyun Yang
  Intestinal Research.2017; 15(3): 338.     CrossRef
• Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn’s Disease: Results from the CONNECT Study
  Jee Hye Kwon, Jong Pil Im, Byong Duk Ye, Jae Hee Cheon, Hyun Joo Jang, Kang Moon Lee, You Sun Kim, Sang Wook Kim, Young Ho Kim, Geun Am Song, Dong Soo Han, Won Ho Kim, Joo Sung Kim
  Gut and Liver.2016; 10(4): 595.     CrossRef
• Crohn's disease confined to the duodenum: A case report
  Dong Jin Song, Il Soon Whang, Hyung Wook Choi, Cheol Yun Jeong, Sung Hoon Jung
  World Journal of Clinical Cases.2016; 4(6): 146.     CrossRef
• Importance of Patients’ Knowledge of Their Prescribed Medication in Improving Treatment Adherence in Inflammatory Bowel Disease
  Chung Hyun Tae, Sung-Ae Jung, Hye Sung Moon, Jung-A Seo, Hye Kyung Song, Chang Mo Moon, Seong-Eun Kim, Ki-Nam Shim, Hye-Kyung Jung
  Journal of Clinical Gastroenterology.2016; 50(2): 157.     CrossRef
• Fusobacterium Isolates Recovered From Colonic Biopsies of Inflammatory Bowel Disease Patients in Korea
  Yangsoon Lee, Chang Soo Eun, A Reum Lee, Chan Hyuk Park, Dong Soo Han
  Annals of Laboratory Medicine.2016; 36(4): 387.     CrossRef
• Crohn's disease prognosis and early immunomodulator therapy: Results from the CONNECT study
  Bun Kim, Jae Hee Cheon, Hyun Jin Moon, Yi Rang Park, Byong Duk Ye, Suk‐Kyun Yang, Geom Seog Seo, Byung Ik Jang, You Sun Kim, Joo Sung Kim, Dong Soo Han, Young‐Ho Kim, Won Ho Kim
  Journal of Gastroenterology and Hepatology.2016; 31(1): 126.     CrossRef

Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients. These studies showed that tacrolimus has excellent short-term efficacy in corticosteroid-refractory patients, with the rates of clinical response ranging from 61% to 96%. However, the long-term prognosis of patients treated with tacrolimus is disappointing, and almost 50% of patients eventually underwent colectomy in long-term follow-up. Tacrolimus can achieve mucosal healing in 40-50% of patients, and this is associated with a favorable long-term prognosis. Anti-tumor necrosis factor (TNF)-α antibodies are another therapeutic option in corticosteroid-refractory patients. A prospective head-to-head comparative study of tacrolimus and infliximab is currently being performed to determine which treatment is more effective in corticosteroid-refractory patients. Several retrospective studies have demonstrated that switching between tacrolimus and anti-TNF-α antibody therapy was effective in patients who were refractory to one of the treatments. Most adverse events of tacrolimus are mild; however, opportunistic infections, especially pneumocystis pneumonia, are the most important adverse events, and these should be carefully considered during treatment. Several issues on tacrolimus treatment in UC patients remain unsolved (e.g., use of tacrolimus as remission maintenance therapy). Further controlled studies are needed to optimize the use of tacrolimus for the treatment of UC.

Citations

Citations to this article as recorded by  

• Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study
  Naoki Oshima, Sakiko Hiraoka, Ryohei Hayashi, Sakuma Takahashi, Manabu Ishii, Shinichi Hashimoto, Kazuo Yashima, Shoko Igawa, Toshihiro Inokuchi, Yoshitaka Ueno, Tomoki Inaba, Hiroshi Matsumoto, Kousaku Kawashima, Taro Takami, Hajime Isomoto, Akiko Shiota
  Inflammatory Bowel Diseases.2024; 30(7): 1087.     CrossRef
• Exploring the therapeutic potential of Anastatica hierochuntica essential oil in DSS-induced colitis
  Abdelrahim Alqudah, Esam Qnais, Omar Gammoh, Yousra Bseiso, Mohammed Wedyan, Mohammed Alqudah, Muna Oqal, Rawan Abudalo, Shtaywy S. Abdalla
  Inflammopharmacology.2024; 32(3): 2035.     CrossRef
• Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review
  Javier P Gisbert, María José García, María Chaparro
  Journal of Crohn's and Colitis.2023; 17(6): 972.     CrossRef
• Gastrointestinal tract and viral pathogens
  Gowthami Sai Kogilathota Jagirdhar, Yashwitha Sai Pulakurthi, Himaja Dutt Chigurupati, Salim Surani
  World Journal of Virology.2023; 12(3): 136.     CrossRef
• Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection
  Ting Xue, Xiaomei Kong, Liang Ma
  Journal of Fungi.2023; 9(8): 812.     CrossRef
• Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease
  Florian Uellendahl-Werth, Carlo Maj, Oleg Borisov, Simonas Juzenas, Eike Matthias Wacker, Isabella Friis Jørgensen, Tim Alexander Steiert, Saptarshi Bej, Peter Krawitz, Per Hoffmann, Christoph Schramm, Olaf Wolkenhauer, Karina Banasik, Søren Brunak, Stefa
  Communications Biology.2022;[Epub]     CrossRef
• Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA–PABA–MAC and 5-ASA–PABA–Diamine for the Treatment of Ulcerative Colitis
  Jiaxing Zhao, Bing Zhang, Qing Mao, Kunqi Ping, Peng Zhang, Fengwei Lin, Dan Liu, Yao Feng, Ming Sun, Yan Zhang, Qiu Hua Li, Tingjian Zhang, Yanhua Mou, Shaojie Wang
  Journal of Medicinal Chemistry.2022; 65(6): 4926.     CrossRef
• Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis
  Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, Mirela Pana, Rehab Gasiea, Gordon William Moran
  Cochrane Database of Systematic Reviews.2022;[Epub]     CrossRef
• Combination tacrolimus and ustekinumab therapy is effective in inducing clinical, biochemical and endoscopic remission in refractory moderate to severe ulcerative colitis
  Rachit Gupta, Julien D. Schulberg, Ola Niewiadomski, Emily K. Wright
  Autoimmunity Reviews.2022; 21(7): 103115.     CrossRef
• Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis
  Sujaata Dwadasi, Maryam Zafer, Donald Goens, Raghavendra Paknikar, Sushila Dalal, Russell D Cohen, Joel Pekow, David T Rubin, Atsushi Sakuraba, Dejan Micic
  Inflammatory Bowel Diseases.2021; 27(10): 1620.     CrossRef
• Treatment of acute severe ulcerative colitis
  Jun-Rong Li, Fang-Mei Ling, Yi-Dong Chen, Ming-Yang Xu, Liang-Ru Zhu
  World Chinese Journal of Digestology.2021; 29(2): 87.     CrossRef
• Role of Topical Tacrolimus in the Management of Proctitis, Perianal Manifestations in Crohn's Disease, and Chronic Pouchitis: A Systematic Review
  George Salem, Kai Ding, Atsushi Sakuraba, Russell Cohen
  Journal of Investigative Medicine.2021; 69(4): 796.     CrossRef
• The Optimal Dose of Tacrolimus in Combination Therapy with an Anti-TNFα Antibody in a Mouse Colitis Model
  Yuki Murakami, Mikihiro Fujiya, Hiroaki Konishi, Shotaro Isozaki, Yuya Sugiyama, Yu Kobayashi, Takahiro Sasaki, Takehito Kunogi, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura
  Biological and Pharmaceutical Bulletin.2021; 44(4): 564.     CrossRef
• Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis
  Roberto Manzini, Marlene Schwarzfischer, Kirstin Atrott, Andrea Laimbacher, Silvia Lang, Marcin Wawrzyniak, Andreas Rickenbacher, Matthias Turina, Petr Hruz, Donata Lissner, Britta Siegmund, Gerhard Rogler, Michael Scharl, Marianne R Spalinger
  Inflammatory Bowel Diseases.2021; 27(12): 1986.     CrossRef
• The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients
  Maizumi Furuse, Shuhei Hosomi, Yu Nishida, Shigehiro Itani, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Noriko Kamata, Toshio Watanabe, Kenji Watanabe, Yasuhiro Fujiwara, Erika Cecchin
  PLOS ONE.2021; 16(4): e0250597.     CrossRef
• De Novo Inflammatory Bowel Disease Rarely Occurs During Posttransplant Immunosuppression
  Jiayun M Fang, Laura Lamps, Amoah Yeboah-Korang, Jerome Cheng, Maria Westerhoff
  American Journal of Clinical Pathology.2021; 156(6): 1113.     CrossRef
• Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis
  Sara Hone Lopez, Gursah Kats-Ugurlu, Remco J. Renken, Henk J. Buikema, Marco R. de Groot, Marijn C. Visschedijk, Gerard Dijkstra, Mathilde Jalving, Jacco J. de Haan
  Virchows Archiv.2021; 479(6): 1119.     CrossRef
• Protective effects of selenium in tacrolimus-induced lung toxicity: potential role of heme oxygenase 1
  Salwa Abdel-Tawab Ibrahim, Nashwa Fathy Eltahawy, Ahlam Mohamed Abdalla, Hanaa Mohamed Khalaf
  Canadian Journal of Physiology and Pharmacology.2021; 99(10): 1069.     CrossRef
• Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review
  Biyu Wu, Jinglu Tong, Zhihua Ran
  Inflammatory Bowel Diseases.2020; 26(1): 24.     CrossRef
• Simple water‐based tacrolimus enemas for refractory proctitis
  Sasha R. Fehily, Felicity C. Martin, Michael A. Kamm
  JGH Open.2020; 4(4): 561.     CrossRef
• Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody
  Miki Kojima, Satoru Oji, Satoru Tanaka, Shoko Izaki, Baku Hashimoto, Hikoaki Fukaura, Kyoichi Nomura
  Multiple Sclerosis and Related Disorders.2020; 39: 101907.     CrossRef
• Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis
  Keiichi Haga, Tomoyoshi Shibuya, Kei Nomura, Koki Okahara, Osamu Nomura, Dai Ishikawa, Naoto Sakamoto, Taro Osada, Akihito Nagahara
  Journal of Clinical Medicine.2020; 9(6): 1771.     CrossRef
• Inflammatory Bowel Disease – Non-biological treatment
  Fernando Magro, Gonçalo Cordeiro, Andreia Martins Dias, Maria Manuela Estevinho
  Pharmacological Research.2020; 160: 105075.     CrossRef
• Lactobacillus plantarum L15 Alleviates Colitis by Inhibiting LPS-Mediated NF-κB Activation and Ameliorates DSS-Induced Gut Microbiota Dysbiosis
  Peng Yu, Chuxin Ke, Jiaxin Guo, Xiuling Zhang, Bailiang Li
  Frontiers in Immunology.2020;[Epub]     CrossRef
• 3D Printed Tacrolimus Rectal Formulations Ameliorate Colitis in an Experimental Animal Model of Inflammatory Bowel Disease
  Iria Seoane-Viaño, Noemí Gómez-Lado, Héctor Lázare-Iglesias, Xurxo García-Otero, José Ramón Antúnez-López, Álvaro Ruibal, Juan Jesús Varela-Correa, Pablo Aguiar, Abdul W. Basit, Francisco J. Otero-Espinar, Miguel González-Barcia, Alvaro Goyanes, Asteria L
  Biomedicines.2020; 8(12): 563.     CrossRef
• A Phase 1, Multiple‐Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis
  Kiyonori Kobayashi, Yasuo Suzuki, Kenji Watanabe, Kazunori Oda, Miyuki Mukae, Akihiro Yamada, Hirokazu Yamagami, Akira Nishimura, Hiroyuki Okamoto
  The Journal of Clinical Pharmacology.2019; 59(2): 271.     CrossRef
• Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease
  Britt Christensen, Peter R. Gibson, Dejan Micic, Ruben J. Colman, Sarah R. Goeppinger, Olufemi Kassim, Andres Yarur, Christopher R. Weber, Russell D. Cohen, David T. Rubin
  Clinical Gastroenterology and Hepatology.2019; 17(3): 486.     CrossRef
• The protective role of phloretin against dextran sulfate sodium-induced ulcerative colitis in mice
  Zecai Zhang, Shan Li, Hongyang Cao, Peng Shen, Jiuxi Liu, Yunhe Fu, Yongguo Cao, Naisheng Zhang
  Food & Function.2019; 10(1): 422.     CrossRef
• Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction
  Yu Nishida, Shuhei Hosomi, Hirokazu Yamagami, Naoko Sugita, Shigehiro Itani, Tomomi Yukawa, Koji Otani, Yasuaki Nagami, Fumio Tanaka, Koichi Taira, Noriko Kamata, Tetsuya Tanigawa, Toshio Watanabe, Yasuhiro Fujiwara, Emiko Mizoguchi
  PLOS ONE.2019; 14(3): e0213505.     CrossRef
• Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis
  Peter Hoffmann, Cyrill Wehling, Johannes Krisam, Jan Pfeiffenberger, Nina Belling, Annika Gauss
  World Journal of Gastroenterology.2019; 25(13): 1603.     CrossRef
• Advances in research of tacrolimus for treatment of inflammatory bowel disease
  Jing-Jing Wang, Yi-Hong Fan
  World Chinese Journal of Digestology.2019; 27(13): 842.     CrossRef
• Toosendanin alleviates dextran sulfate sodium-induced colitis by inhibiting M1 macrophage polarization and regulating NLRP3 inflammasome and Nrf2/HO-1 signaling
  Huining Fan, Wei Chen, Jinshui Zhu, Jing Zhang, Shiqiao Peng
  International Immunopharmacology.2019; 76: 105909.     CrossRef
• Pharmacotherapy of ulcerative colitis – current status and emerging trends
  Hilal Ahmad, Vijay L. Kumar
  Journal of Basic and Clinical Physiology and Pharmacology.2018; 29(6): 581.     CrossRef
• Updated treatment strategies for intestinal Behçet’s disease
  Yong Eun Park, Jae Hee Cheon
  The Korean Journal of Internal Medicine.2018; 33(1): 1.     CrossRef
• Tacrolimus: An updated review on delivering strategies for multifarious diseases
  Divya Dheer, Jyoti, Prem N. Gupta, Ravi Shankar
  European Journal of Pharmaceutical Sciences.2018; 114: 217.     CrossRef
• Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis
  Yi-Juan Liu, Hua Fan, Wei-Wei Zhen, Xing Yu, Jin-Tong Chen, Cheng-Dang Wang
  Medicine.2018; 97(32): e11440.     CrossRef
• Long-lasting Immunosuppressive Effects of tacrolimus-loaded Micelle NK61060 in Preclinical Arthritis and Colitis Models
  Takamichi Sato, Junpei Konno, Akihiro Sekiguchi, Nao Yoneki, Kana Kawano, Tomohiro Hayashi, Yukina Ogawa, Aya Kikitsu, Takashi Aijima, Kazuhisa Hara, Shintaro Hara, Hitomi Hayashi, Kimiko Fuchigami, Naoko Igo, Yuki Takashima, Yuki Kobayashi, Masayuki Mori
  Therapeutic Delivery.2018; 9(10): 711.     CrossRef
• In Vivo Study of the Efficacy of the Essential Oil of Zanthoxylum bungeanum Pericarp in Dextran Sulfate Sodium-Induced Murine Experimental Colitis
  Zecai Zhang, Peng Shen, Jiuxi Liu, Cong Gu, Xiaojie Lu, Yanxin Li, Yongguo Cao, Bo Liu, Yunhe Fu, Naisheng Zhang
  Journal of Agricultural and Food Chemistry.2017; 65(16): 3311.     CrossRef
• Significant contribution of TRPC6 channel-mediated Ca²⁺ influx to the pathogenesis of Crohn’s disease fibrotic stenosis
  Lin Hai Kurahara, Keizo Hiraishi, Miho Sumiyoshi, Mayumi Doi, Yaopeng Hu, Kunihiko Aoyagi, Yuwen Jian, Ryuji Inoue
  Journal of Smooth Muscle Research.2016; 52: 78.     CrossRef

Proton pump inhibitors (PPIs) are widely used though an association with hypomagnesaemia and hypocalcaemia has only been described since 2006. Patients typically present after years of stable dosing with musculoskeletal, neurological or cardiac arrhythmic symptoms, but it is likely that many cases are under-recognised. Magnesium levels resolve rapidly on discontinuation of PPI therapy and hypomagnesaemia recurs rapidly on rechallenge with any agent in the class. The cellular mechanisms of magnesium homeostasis are increasingly being understood, including both passive paracellular absorption through claudins and active transcellular transporters, including the transient receptor potential channels (TRPM6) identified in the intestine and nephron. PPIs may alter luminal pH by modulating pancreatic secretions, affecting non-gastric H+K+ATPase secretion, altering transporter transcription or channel function. A small reduction in intestinal absorption appears pivotal in causing cumulative deficiency. Risk factors have been associated to help identify patients at risk of this effect but clinical vigilance remains necessary for diagnosis.

Citations

Citations to this article as recorded by  

• Use of Acid-Suppression Therapy and Odds of Migraine and Severe Headache in the National Health and Nutrition Examination Survey
  Margaret Slavin, Cara L. Frankenfeld, Alexander B. Guirguis, Elizabeth K. Seng
  Neurology Clinical Practice.2024;[Epub]     CrossRef
• Magnesium Homeostasis
  Aubrey R. Morrison
  Clinical Journal of the American Society of Nephrology.2023; 18(7): 969.     CrossRef
• Risk of urinary stone formation associated to proton pump inhibitors: A systematic review and metanalysis
  Rawa Bapir, Kamran Hassan Bhatti, Ahmed Eliwa, Herney Andrés García-Perdomo, Nazim Gherabi, Derek Hennessey, Vittorio Magri, Panagiotis Mourmouris, Adama Ouattara, Gianpaolo Perletti, Joseph Philipraj, Konstantinos Stamatiou, Musliu Adetola Tolani, Lazaro
  Archivio Italiano di Urologia e Andrologia.2022; 94(4): 507.     CrossRef
• An overview of diagnosis and management of drug‐induced hypomagnesemia
  George Liamis, Ewout J. Hoorn, Matilda Florentin, Haralampos Milionis
  Pharmacology Research & Perspectives.2021;[Epub]     CrossRef
• Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease
  Yi-Chao Shi, Shun-Tian Cai, Ya-Ping Tian, Hui-Jun Zhao, Yan-Bing Zhang, Jing Chen, Rong-Rong Ren, Xi Luo, Li-Hua Peng, Gang Sun, Yun-Sheng Yang
  Genomics, Proteomics & Bioinformatics.2019; 17(1): 52.     CrossRef
• Atrial fibrillation and gastrooesophageal reflux disease: association mechanisms, treatment approaches
  O. N. Antropova, N. V. Pyrikova, I. V. Osipova
  Russian Journal of Cardiology.2019; (7): 103.     CrossRef
• Do stop me now: gastric acid-reducing drugs following renal transplantation
  Ines Held, Rhodri Pyart
  Journal of Kidney Care.2018; 3(1): 6.     CrossRef
• Magnesium homeostasis in cattle: absorption and excretion
  Holger Martens, Sabine Leonhard-Marek, Monika Röntgen, Friederike Stumpff
  Nutrition Research Reviews.2018; 31(1): 114.     CrossRef
• A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
  Li-Yuan Yu, Lu-Ning Sun, Xue-Hui Zhang, Yue-Qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hong-Wen Zhang, Yong-Qing Wang
  Advances in Therapy.2017; 34(5): 1070.     CrossRef
• Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis
  Young Joo Yang, Chang Seok Bang, Gwang Ho Baik, Tae Young Park, Suk Pyo Shin, Ki Tae Suk, Dong Joon Kim
  BMC Gastroenterology.2017;[Epub]     CrossRef
• Proton Pump Inhibitors Should be Used with Caution in Critically Ill Patients to Prevent the Risk of Clostridium difficile Infection
  Jung Hwa Min, You Sun Kim
  Gut and Liver.2016; 10(4): 493.     CrossRef
• Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats: Pilot Study
  Cheol Min Shin, Nayoung Kim, Yong Sung Kim, Ryoung Hee Nam, Ji Hyun Park, Dong Ho Lee, Yeong-Jae Seok, Yeon-Ran Kim, Joo-Hyon Kim, Jung Min Kim, Joo Sung Kim, Hyun Chae Jung
  Gut and Liver.2016; 10(6): 896.     CrossRef

Citations

Citations to this article as recorded by  

• Roles of Inflammasomes in Epstein–Barr Virus-Associated Nasopharyngeal Cancer
  Chin King Looi, Ling-Wei Hii, Felicia Fei-Lei Chung, Chun-Wai Mai, Wei-Meng Lim, Chee-Onn Leong
  Cancers.2021; 13(8): 1786.     CrossRef
• Computational investigation of FDA approved drugs as selective PARP-1 inhibitors by targeting BRCT domain for cancer therapy
  Chandan Kumar, P.T.V. Lakshmi, Annamalai Arunachalam
  Journal of Molecular Graphics and Modelling.2021; 108: 107919.     CrossRef
• Identification of Autophagy-Associated Biomarkers and Corresponding Regulatory Factors in the Progression of Colorectal Cancer
  Chunrui Zhang, Jing Jiang, Liqiang Wang, Liyu Zheng, Jiankai Xu, Xiaolin Qi, Huiying Huang, Jianping Lu, Kongning Li, Hong Wang
  Frontiers in Genetics.2020;[Epub]     CrossRef
• Anticancer and apoptotic activities of parthenolide in combination with epirubicin in mda-mb-468 breast cancer cells
  Arash Ghorbani-Abdi-Saedabad, Mohammad Yahya Hanafi-Bojd, Negin Parsamanesh, Zahra Tayarani-Najaran, Homa Mollaei, Reyhane Hoshyar
  Molecular Biology Reports.2020; 47(8): 5807.     CrossRef
• Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies
  Malgorzata Sztiller-Sikorska, Malgorzata Czyz
  Pharmaceuticals.2020; 13(8): 194.     CrossRef
• Integration of genetic variants and gene network for drug repurposing in colorectal cancer
  Lalu Muhammad Irham, Henry Sung-Ching Wong, Wan-Hsuan Chou, Wirawan Adikusuma, Eko Mugiyanto, Wan-Chen Huang, Wei-Chiao Chang
  Pharmacological Research.2020; 161: 105203.     CrossRef
• Synthesis of azo dyes possessing N-heterocycles and evaluation of their anticancer and antibacterial properties
  Zarrin Ghasemi, Sajjad Azizi, Roya Salehi, Hossein Samadi Kafil
  Monatshefte für Chemie - Chemical Monthly.2018; 149(1): 149.     CrossRef
• Parthenolide attenuated bleomycin-induced pulmonary fibrosis via the NF-κB/Snail signaling pathway
  Xiao-he Li, Ting Xiao, Jia-huan Yang, Yuan Qin, Jing-jing Gao, Hui-juan Liu, Hong-gang Zhou
  Respiratory Research.2018;[Epub]     CrossRef
• Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth
  Eun-Kyung Kim, Jae Hee Cho, EuiJoo Kim, Yoon Jae Kim, Aamir Ahmad
  PLOS ONE.2017; 12(7): e0181183.     CrossRef
• Dietary selenium protects adiponectin knockout mice against chronic inflammation induced colon cancer
  Arpit Saxena, Raja Fayad, Kamaljeet Kaur, Samantha Truman, Julian Greer, James A. Carson, Anindya Chanda
  Cancer Biology & Therapy.2017; 18(4): 257.     CrossRef
• Sesquiterpene binding Gly-Leu-Ser/Lys-“co-adaptation pocket” to inhibit lung cancer cell epithelial-mesenchymal transition
  Xiao-Yu Ai, Heng Zhang, Shao-Yan Gao, Yuan Qin, Wei-Long Zhong, Ju Gu, Meng Li, Kai-Liang Qiao, Qin Tian, Zhan-Hong Cui, Jia-Huan Yang, Zhun Bi, Ting Xiao, Shuang Chen, Hui-Juan Liu, Hong-Gang Zhou, Tao Sun, Cheng Yang
  Oncotarget.2017; 8(41): 70192.     CrossRef
• Juglanin inhibits lung cancer by regulation of apoptosis, ROS and autophagy induction
  Liang Chen, Ya-Qiong Xiong, Jing Xu, Ji-Peng Wang, Zi-Li Meng, Yong-Qing Hong
  Oncotarget.2017; 8(55): 93878.     CrossRef
• Cyr61 participates in the pathogenesis of acute lymphoblastic leukemia by enhancing cellular survival via the AKT/NF-κB signaling pathway
  Xianjin Zhu, Yanfang Song, Conglian Wu, Chuxi Pan, Pingxia Lu, Meihua Wang, Peizheng Zheng, Rongfen Huo, Chenqing Zhang, Wanting Li, Yulin Lin, Yingping Cao, Ningli Li
  Scientific Reports.2016;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Comprehensive analysis of key host gene-microbe networks in the cecum tissues of the obese rabbits induced by a high-fat diet
  Yanhong Li, Xiaolan Qi, Qinrong Wang, Yan He, Zhupeng Li, Xi Cen, Limin Wei
  Frontiers in Cellular and Infection Microbiology.2024;[Epub]     CrossRef
• IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation
  Jaesuk Yun, Mi Hee Park, Dong Ju Son, Kyung Tak Nam, Dae Bong Moon, Jung Heun Ju, Ok Kyung Hwang, Jeong Soon Choi, Tae Hoon Kim, Young Suk Jung, Dae Yeon Hwang, Sang Bae Han, Do-Young Yoon, Jin Tae Hong
  Cell Death & Disease.2018;[Epub]     CrossRef
• The Correlation of Serum IL-12B Expression With Disease Activity in Patients With Inflammatory Bowel Disease
  Hye Won Lee, Sook Hee Chung, Chang Mo Moon, Xiumei Che, Seung Won Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
  Medicine.2016; 95(23): e3772.     CrossRef

Citations

Citations to this article as recorded by  

• Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis
  Mukesh Kumar Ranjan, Peeyush Kumar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Sandeep K Mundhra, Rithvik Golla, Shubi Virmani, Raju Sharma, Peush Sahni, Prasenjit Das, Mani Kalaivani, Ashish Datt Upadhyay, Govind Makharia, Saurabh Kedia, Vineet Ahuja
  Journal of Crohn's and Colitis.2024; 18(2): 192.     CrossRef
• Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
  Makoto Naganuma, Kenji Watanabe, Satoshi Motoya, Haruhiko Ogata, Toshiyuki Matsui, Yasuo Suzuki, Lyann Ursos, Shigeru Sakamoto, Mitsuhiro Shikamura, Tetsuharu Hori, Jovelle Fernandez, Mamoru Watanabe, Toshifumi Hibi, Takanori Kanai
  Journal of Gastroenterology and Hepatology.2022; 37(1): 81.     CrossRef
• Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
  Satohiro Matsumoto, Hirosato Mashima
  Crohn's & Colitis 360.2021;[Epub]     CrossRef
• Treatment of Inflammatory Bowel Disease: A Comprehensive Review
  Zhaobei Cai, Shu Wang, Jiannan Li
  Frontiers in Medicine.2021;[Epub]     CrossRef
• Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
  Hiroshi Nakase
  Gut and Liver.2020; 14(1): 7.     CrossRef
• The Leading Edge of the Treatment of Inflammatory Bowel Disease
  Hiroshi Nakase
  Nihon Naika Gakkai Zasshi.2020; 109(6): 1145.     CrossRef
• Predictive Role of NUDT15 Variants on Thiopurine-Induced Myelotoxicity in Asian Inflammatory Bowel Disease Patients
  Natalia Sutiman, Sylvia Chen, Khoon Lin Ling, Sai Wei Chuah, Wai Fook Leong, Vinayak Nadiger, Madeline Tjai, Chris San Choon Kong, Brian John Schwender, Webber Chan, Hang Hock Shim, Wee Chian Lim, Chiea Chuen Khor, Yin Bun Cheung, Balram Chowbay
  Pharmacogenomics.2018; 19(1): 31.     CrossRef
• NUDT15,FTO, andRUNX1genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
  Toshiyuki Sato, Tetsuya Takagawa, Yoichi Kakuta, Akihiro Nishio, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Yuko Kita, Takako Miyazaki, Masaki Iimuro, Nobuyuki Hida, Kazutoshi Hori, Hiroki Ikeuchi, Shiro Nakamura
  Intestinal Research.2017; 15(3): 328.     CrossRef
• Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis
  Yoon Jee Lee, Jae Hee Cheon, Jae Hyun Kim, SunHo Yoo, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim
  Yonsei Medical Journal.2017; 58(1): 144.     CrossRef
• Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study
  Caroline Prieux-Klotz, Stéphane Nahon, Aurelien Amiot, Leila Sinayoko, Carole Galéano-Cassaz, Stanislas Chaussade, Romain Coriat, Pierre Lahmek, Vered Abitbol
  Digestive Diseases and Sciences.2017; 62(2): 473.     CrossRef
• Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission
  Jae Hyun Kim, Jae Hee Cheon, Yehyun Park, Hyun Jung Lee, Soo Jung Park, Tae Il Kim, Won Ho Kim
  Scandinavian Journal of Gastroenterology.2016; 51(9): 1069.     CrossRef
• Is Long-Term Therapy With Thiopurines Effective for Maintaining Remission in Patients With Moderate-To-Severe Ulcerative Colitis?
  Seong Ran Jeon, Won Ho Kim
  Intestinal Research.2015; 13(3): 191.     CrossRef

Citations

Citations to this article as recorded by  

• Are the New Biologics Effective in the Management of Postoperative Crohn’s Disease?
  Fadi H Mourad, Rami G Maalouf, Roni Aoun, Paulo Gustavo Kotze, Jana G Hashash
  Inflammatory Bowel Diseases.2024; 30(3): 459.     CrossRef
• How Reliable Is Endoscopic Scoring of Postoperative Recurrence in Crohn Disease?: A Systematic Review and Meta-Analysis
  Eline M. L. van der Does de Willebois, Vittoria Bellato, Marjolijn Duijvestein, Susan van Dieren, Silvio Danese, Pierpaolo Sileri, Christianne J. Buskens, Andrea Vignali, Willem A. Bemelman
  Annals of Surgery Open.2024; 5(1): e397.     CrossRef
• Trends in Surgical Recurrence Among Pediatric Crohn’s Disease Patients Using Administrative Claims Data
  Matthew D Egberg, Xian Zhang, Michael Phillips, Michael D Kappelman
  Crohn's & Colitis 360.2023;[Epub]     CrossRef
• Optimal strategies to prevent recrudescent Crohn's disease after resection
  Natália Sousa Freitas Queiroz, Takayuki Yamamoto, Paulo Gustavo Kotze
  Seminars in Colon and Rectal Surgery.2020; 31(2): 100746.     CrossRef
• Profile of Consecutive Fecal Calprotectin Levels in the Perioperative Period and Its Predictive Capacity for Early Endoscopic Recurrence in Crohn’s Disease
  Ruiqing Liu, Zhen Guo, Lei Cao, Zhiming Wang, Jianfeng Gong, Yi Li, Weiming Zhu
  Diseases of the Colon & Rectum.2019; 62(3): 318.     CrossRef
• Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
  Sakiko Hiraoka, Shiho Takashima, Yoshitaka Kondo, Toshihiro Inokuchi, Yuusaku Sugihara, Masahiro Takahara, Seiji Kawano, Keita Harada, Jun Kato, Hiroyuki Okada
  Intestinal Research.2018; 16(1): 75.     CrossRef
• Factors affecting the incidence of early endoscopic recurrence after ileocolonic resection for Crohn's disease: a multicentre observational study
  I. F. de Barcelos, P. G. Kotze, A. Spinelli, Y. Suzuki, F. V. Teixeira, I. C. de Albuquerque, R. Saad‐Hossne, L. M. da Silva Kotze, T. Yamamoto
  Colorectal Disease.2017;[Epub]     CrossRef
• Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn’s Disease: Results from the CONNECT Study
  Jee Hye Kwon, Jong Pil Im, Byong Duk Ye, Jae Hee Cheon, Hyun Joo Jang, Kang Moon Lee, You Sun Kim, Sang Wook Kim, Young Ho Kim, Geun Am Song, Dong Soo Han, Won Ho Kim, Joo Sung Kim
  Gut and Liver.2016; 10(4): 595.     CrossRef

Citations

Citations to this article as recorded by  

• Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis
  Mukesh Kumar Ranjan, Peeyush Kumar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Sandeep K Mundhra, Rithvik Golla, Shubi Virmani, Raju Sharma, Peush Sahni, Prasenjit Das, Mani Kalaivani, Ashish Datt Upadhyay, Govind Makharia, Saurabh Kedia, Vineet Ahuja
  Journal of Crohn's and Colitis.2024; 18(2): 192.     CrossRef
• Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review
  Julien D Schulberg, Emily K Wright, Bronte A Holt, Helen E Wilding, Amy L Hamilton, Alyson L Ross, Michael A Kamm
  Journal of Gastroenterology and Hepatology.2021; 36(2): 344.     CrossRef
• Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study
  Hee Seung Hong, Kyuwon Kim, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
  Therapeutic Advances in Gastroenterology.2021;[Epub]     CrossRef
• NUDT15,FTO, andRUNX1genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
  Toshiyuki Sato, Tetsuya Takagawa, Yoichi Kakuta, Akihiro Nishio, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Yuko Kita, Takako Miyazaki, Masaki Iimuro, Nobuyuki Hida, Kazutoshi Hori, Hiroki Ikeuchi, Shiro Nakamura
  Intestinal Research.2017; 15(3): 328.     CrossRef
• Importance of Patients’ Knowledge of Their Prescribed Medication in Improving Treatment Adherence in Inflammatory Bowel Disease
  Chung Hyun Tae, Sung-Ae Jung, Hye Sung Moon, Jung-A Seo, Hye Kyung Song, Chang Mo Moon, Seong-Eun Kim, Ki-Nam Shim, Hye-Kyung Jung
  Journal of Clinical Gastroenterology.2016; 50(2): 157.     CrossRef

Citations

Citations to this article as recorded by  

• Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management
  Jihye Park, Sinyoung Park, Shin Ae Lee, Soo Jung Park, Jae Hee Cheon
  The Korean Journal of Internal Medicine.2021; 36(5): 1040.     CrossRef
• Evaluation of Serious Adverse Event Reporting Forms for Clinical Trials: A Comparative Korean Study
  Heeyoung Lee, Cholong Park, Jinwon Choi, Seongeun Jeong, Hyunin Cho, Wooseong Huh, Eunyoung Kim
  Journal of Empirical Research on Human Research Ethics.2020; 15(5): 415.     CrossRef
• ‘Screening audit’ as a quality assurance tool in good clinical practice compliant research environments
  Sinyoung Park, Chung Mo Nam, Sejung Park, Yang Hee Noh, Cho Rong Ahn, Wan Sun Yu, Bo Kyung Kim, Seung Min Kim, Jin Seok Kim, Sun Young Rha
  BMC Medical Ethics.2018;[Epub]     CrossRef

Intestinal pseudo-obstruction (IPO) is an uncommon, severe complication that occurs in a small subgroup of patients with systemic lupus erythematosus (SLE). To our knowledge, approximately 30 cases of IPO in SLE have been reported in the literature. Moreover, IPO is rare as an initial manifestation of SLE. We report a case of a 43-year-old woman with SLE who initially presented with IPO.

Citations

Citations to this article as recorded by  

• Intestinal pseudo-obstruction as systemic lupus erythematosus complication: is it time to reconsider the role of surgery?: A case report of a tailored multidisciplinary managed 44-year-old male patient
  Mario Romeo, Marcello Dallio, Raffaele Pellegrino, Francesco Saverio Lucido, Simona Parisi, Claudio Gambardella, Iacopo Panarese, Anna Russo, Ludovico Docimo, Alessandro Federico
  Medicine: Case Reports and Study Protocols.2024; 5(5): e00322.     CrossRef
• An Atypical Initial Manifestation of Systemic Lupus Erythematosus: Lupus Enteritis Accompanied by Intestinal Pseudo-Obstruction and Bilateral Hydronephroureter
  Faiza Naeem, Mishkawt U Noor, Shabnam Batool, Saira E Anwer Khan, Muhammad Akmal
  Cureus.2023;[Epub]     CrossRef
• RETRACTED ARTICLE: A hybrid machine learning framework to predict mortality in paralytic ileus patients using electronic health records (EHRs)
  Fahad Shabbir Ahmad, Liaqat Ali, Raza-Ul-Mustafa, Hasan Ali Khattak, Tahir Hameed, Iram Wajahat, Seifedine Kadry, Syed Ahmad Chan Bukhari
  Journal of Ambient Intelligence and Humanized Computing.2021; 12(3): 3283.     CrossRef
• Early Intervention and Resolution of Pediatric Intestinal Pseudo-Obstruction in Systemic Lupus Erythematosus: A Pediatric Case Report
  Diane Hsu, Uptej K. Khalsa, Maheen Hassan, Christy I. Sandborg, Shweta S. Namjoshi
  JPGN Reports.2021; 2(1): e041.     CrossRef
• Intestinal pseudo‐obstruction: Unusual presentation of systemic lupus erythematous
  Myriam Ayari, Abdelwaheb Nakhli, Zeineb Teyeb, Imen Abdelaali, Syrine Bellakhal, Taieb Jomni
  Clinical Case Reports.2021; 9(3): 1759.     CrossRef
• Intestinal pseudo-obstruction as the initial manifestation of systemic lupus erythematosus
  Fang-jie Zhang, Juan Zhang, Li-ping Zhou, Ai-Min Wang, Xiang-min Li
  The American Journal of Emergency Medicine.2019; 37(1): 176.e1.     CrossRef
• Lupus intestinal pseudo-obstruction and hydronephrosis
  Brittany L. Adler, Homa Timlin, Julius Birnbaum
  Medicine.2019; 98(28): e16178.     CrossRef
• Gastrointestinal system involvement in systemic lupus erythematosus
  Z Li, D Xu, Z Wang, Y Wang, S Zhang, M Li, X Zeng
  Lupus.2017; 26(11): 1127.     CrossRef

Familial Mediterranean fever (FMF) is an inherited autosomal recessive disorder, ethnically restricted and commonly found among populations surrounding the Mediterranean Sea. FMF is the most prevalent autoinflammatory disease; is characterized by recurrent, self-limited episodes of fever with serositis; and is caused by Mediterranean fever gene (MEFV) mutations on chromosome 16. We describe a case of adult-onset FMF with complete symptomatic remission during pregnancy, without the use of colchicine. A 25-year-old woman had presented with periodic fever, abdominal pain, and vomiting since she was 21. Her abdominal computed tomography scan showed intestinal nonrotation. She underwent exploratory laparotomy and appendectomy for her symptoms 1 year prior. She had a symptom-free pregnancy period, but abdominal pain and fever recurred after delivery. Mutation analysis of the MEFV gene revealed two point mutations (p.Leu110Pro and p.Glu148Gln). We report an adult female patient with FMF in Korea with complete symptomatic remission during pregnancy.

Citations

Citations to this article as recorded by  

• Inherited Autoinflammatory Disease with Immunodeficiency Combined with IgA Nephropathy
  Zhifeng Jiang, Aiqiao Feng, L I Tao
  Aktuelle Rheumatologie.2020; 45(06): 574.     CrossRef
• A Case of Schnitzler's Syndrome without Monoclonal Gammopathy-Associated Chronic Urticaria Treated with Anakinra
  Min Joo Ahn, Ji Eun Yu, Jiung Jeong, Da Woon Sim, Young-Il Koh
  Yonsei Medical Journal.2018; 59(1): 154.     CrossRef
• Thiol/disulphide homeostasis in pregnant women with Familial Mediterranean fever
  Aykan Yucel, Cem Yasar Sanhal, Korkut Daglar, Ozgur Kara, Dilek Uygur, Ozcan Erel
  Redox Report.2016; 21(6): 287.     CrossRef